Lymphoma
Ansell SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med 2022;387:310-20. Abstract
Bachy E et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: Results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol 2022;40(3):242-51. Abstract
Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study. ASH 2022;Abstract 610.
Batlevi CL et al. Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma. ASH 2022;Abstract 954.
Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica 2023;[Online ahead of print]. Abstract
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387:2220-31. Abstract
Dreyling M et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized triangle trial by the European MCL Network. ASH 2022;Abstract 1.
Dreyling M et al. Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the elara trial. ASH 2022;Abstract 608.
Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety in the phase II L-MIND study. Haematolgica 2023;[Online ahead of print]. Abstract
Herrera AF et al. Exploratory analysis of factors influencing efficacy and safety of camidanlumab tesirine: Data from the open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL). ASH2022;Abstract 542.
Jain P et al. Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma—A phase II clinical trial. ICML 2023;Abstract 099.
Neelapu SS et al. 3-year follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2022;Abstract 4660.
Philips T et al. Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial. ASCO2023;Abstract 7546.
Phillips T et al. Improvements in lymphoma symptoms and health-related quality of life in patients with relapsed or refractory large B-cell lymphoma treated with subcutaneous epcoritamab (EPCORE NHL-1). ASH 2022;Abstract 74.
Qualls DA et al. Tafasitamab and lenalidomide in large B cell lymphoma: Real-world outcomes in a multicenter retrospective study. Blood 2023;2023021274. Abstract
Ruan J et al. Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naïve mantle cell lymphoma. ASH 2022;Abstract 73.
Shore N et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.
Song Y et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study. Blood 2022;139(21):3148-58. Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386:351-63. Abstract
Wang M et al. Acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve (TN) mantle cell lymphoma (MCL): 2-year safety and efficacy analysis. Blood 2022;140 (Supplement 1):6477-9. Abstract
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386:2482-94. Abstract
Urothelial Bladder Cancer and Renal Cell Carcinoma
Albiges L et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2023;24(8);881-91. Abstract
Braun DA et al. Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study. ASCO 2023;Abstract 4524.
Choueiri TK et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med 2023;388:1767-78. Abstract
Choueiri T et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). ESMO 2022;Abstract LBA8.
Flach R et al. The CONFIDENT-P trial: Clinical implementation of artificial intelligence assistance in prostate cancer pathology. Genitourinary Cancers Symposium 2023;Abstract TPS405.
Grivas P et al. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. Genitourinary Cancers Symposium 2023;Abstract 518.
Hoimes CJ et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol 2022;41(1):22-31. Abstract
Lee C-H et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. ASCO 2023;Abstract 4537.
Loriot Y et al. Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). ASCO 2023;Abstract 4514.
McGregor BA et al. Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study. Genitourinary Cancers Symposium 2023;Abstract 684.
Petrylak DP et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. Genitourinary Cancers Symposium 2023;Abstract 520.
Powles T et al. Avelumab first-line maintenance for advanced urothelial carcinoma: Results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. J Clin Oncol 2023;41(19):3486-92. Abstract
Powles T et al. Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk. Genitourinary Cancers Symposium 2023;Abstract 605.
Rosenberg JE et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 2023;[Online ahead of print]. Abstract
Rosenberg JE et al. Study EV-103 cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). ESMO 2022;Abstract LBA73.
Sharma M et al. A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab. ESMO 2022;Abstract 481P.
Sheng X et al. Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. ASCO 2022;Abstract 4518.
Shore ND et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.
Tagawa ST et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Genitourinary Cancers Symposium 2023;Abstract 526.
Tagawa ST et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39(22):2474-85. Abstract
Van der Heijden M et al. Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase 3 CheckMate 901 trial. ESMO 2023;LBA7.
Hepatobiliary and Pancreatic Cancers
Abou Alfa GK et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Gastrointestinal Cancers Symposium 2022;Abstract 379.
Babiker H et al. Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer. ASCO 2023;Abstract TPS4199.
Bang YH et al. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:17588359221097934. Abstract
Chow P et al. IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. AACR 2023;Abstract CT003.
Gkika E et al. Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study. Cancers 2022;14(6):1568. Abstract
Harding JJ et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study. Lancet Oncol 2023;24(7):772-82. Abstract
Hosein AN et al. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer 2022;3(3):272-86. Abstract
Kelley RK et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10391):1852-65. Abstract
Kindler HL et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2023;40(34):3929-39. Abstract
Meric-Bernstram F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. ASCO 2023;Abstract LBA3000.
Nakamura Y et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2–positive metastatic biliary tract cancer (SGNTUC-019): A phase II basket study. J Clin Oncol 2023;[Online ahead of print]. Abstract
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022;Abstract 4006.
O’Reilly EM et al. Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. ASCO 2023;Abstract 4006.
Persano M et al. Response to letter entitled Re: sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer 2023;192:113264. Abstract
Qin S et al. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial. ESMO 2022;Abstract LBA35.
Reig M et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93. Abstract
Sangro B et al. How to integrate and sequence new agents in HCC? ESMO GI 2023;Meeting Resource.
Singal AG et al. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Rep (Hoboken) 2022;6(1):e1679. Abstract
Weisser NE et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nature Comm 2023;14:1394. Abstract
Yau T et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23(1):77-90. Abstract
Gynecologic Cancers
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
Eskander RN et al. Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: The phase 3 NRG GY018 study. SGO 2023;Abstract LBA 10.
González-Martín A et al. Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023;189:112908. Abstract
González-Martín A et al. PRIMA/ENGOT-OV26/GOG-3012 Study: Updated long-term PFS and safety. IGCS2022;Abstract S005/1753.
Hardesty MM et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166(2):219-29. Abstract
Ledermann JA et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi24-32. Abstract
Li N et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial. JAMA Oncol 2023;9(9):1230-7. Abstract
Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.
Makker V et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol 2023;41(16):2904-10. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.ASCO2023;Abstract LBA3000.
Mirza MR et al. Dostarlimab in combination with chemotherapy for treatment of primary advanced or recurrent endometrial cancer: A placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). SGO 2023;Abstract LBA 11.
Oaknin A et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: Interim results of the phase I GARNET study. Clin Cancer Res 2023;CCR-22-3915. Abstract
O’Malley DM et al. PARP inhibitors in ovarian cancer: A review. Target Oncol 2023;18(4):471-503. Abstract
O’Malley DM et al. Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158. Ann Oncol 2022;33(suppl_7):S796-7. Abstract
Ray-Coquard I et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92. Abstract
Ray-Coquard I et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ESMO 2022;Abstract LBA29.
Roque DM et al. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Br J Cancer 2022;126(12):1695-703. Abstract
Multiple Myeloma
Chari A et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Phase 1/2 results from MonumenTAL-1. ASH 2022;Abstract 157.
Dhakal B et al. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. ASCO 2023;Abstract LBA106.
Dimopoulos MA et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial. J Clin Oncol 2020;38(34):4030-41. Abstract
Dimopoulos MA et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393(10168):253-64. Abstract
Facon T et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137(26):3616-28. Abstract
Goldschmidt H et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9(11):e810-21. Abstract
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Kaufman JL et al. First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. IMS 2023;Abstract OA-29.
Kaufman JL et al. An updated safety and efficacy analysis of venetoclax plus daratumumab and dexamethasone in an expansion cohort of a phase 1/2 study of patients with t(11;14) relapsed/refractory multiple myeloma. ASH 2022;Abstract 3232.
Kegyes D et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol 2022;15(1):78. Abstract
Lee HC et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8006.
Lesokhin AM et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med 2023;29(9):2259-67. Abstract
Leypoldt LB et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 2023;[Online ahead of print]. Abstract
Lin Y et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8009.
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized, phase 3 study. Blood Cancer J 2023;13(1):72. Abstract
Mateos M-V et al. Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. IMS 2023;Abstract OA-52.
Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract
Richardsson PG et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3):416-27. Abstract
Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:1002-14. Abstract
Rodriguez-Otero P et al. Ide-cel versus standard regimens in triple-class-exposed RRMM: Phase 3 KarMMa-3. European CAR T-Cell Meeting 2023;Abstract BA02-7.
San-Miguel J et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389(4):335-47. Abstract
Schiller GJ et al. Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies. Clin Lymphoma Myeloma Leuk 2023;23(9):e286-96. Abstract
Schinke CD et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstarct 8036.
Usmani S et al. KarMMa-2 cohort 2a: Efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. ASH 2022;Abstract 361.
van de Donk NWCJ et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8011.
Voorhees PM et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10(10):e825-37. Abstract
HER2-Positive and Triple-Negative Breast Cancer
Bardia A et al. Datopotamab deruxtecan (dato-DXd) in advanced triple-negative breast cancer (TNBC): Updated results from the phase 1 TROPION-PanTumor01 study. SABCS 2022;Abstract P6-10-03.
Bardia A et al. Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. ASCO 2022;Abstract 1071.
Bartsch R et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Nat Med 2022;28(9):1840-7. Abstract
Cortes J et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022;387(3):217-26. Abstract
Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract
Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol 2023;[Online ahead of print]. Abstract
Krop IE et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). ASCO 2022;Abstract 1002.
Krop IE et al. Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02. SABCS 2022;Abstract GS2-01.
Lin NU et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol 2023;9(2):197-205. Abstract
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387:9-20. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Robson ME et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 2023;184:39-47. Abstract
Schmid P et al. Datopotamab deruxtecan (dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase 1b/2 study. SABCS 2022;Abstract PD11-09.
Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386:556-67. Abstract
Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO Virtual Plenary 2022;Abstract VP1-2022.